Genital Herpes Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts

DelveInsight's "Genital Herpes Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Genital Herpes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Genital Herpes Market Forecast
https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Genital Herpes Market Report:
• The Genital Herpes market size was valued ~870 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2025, Initial clinical and preclinical data shared at the 35th ESCMID Global Conference in Vienna, Austria, indicate that Assembly Biosciences' ABI-5366-a novel helicase-primase inhibitor (HPI) targeting herpes simplex virus (HSV)-has the potential to reshape treatment for recurrent genital herpes (RGH). Designed for monthly or weekly oral dosing, ABI-5366 shows favorable pharmacokinetics, strong tissue penetration, and high potency at the nanomolar level against both HSV-1 and HSV-2. This candidate could overcome key challenges associated with nucleoside analogues, particularly issues related to treatment adherence and sustained therapeutic effect.
• In May 2024, Sexual health company Wisp has extended its collaboration with TBD Health by providing access to TBD Health's sexually transmitted infection/disease (STI/STD) testing kits through its platform. Under the expanded partnership, Wisp telehealth patients can be referred to TBD Health's in-person clinics for STD testing, PrEP prescriptions, UTI treatments, and additional healthcare services.
• Based on our research, herpes simplex virus (HSV) infection, commonly referred to as herpes, is prevalent globally, impacting almost 225,567,000 individuals in the 7MM as of 2023.
• As per DelveInsight's analysis, around 80% of individuals diagnosed with herpes simplex virus (HSV) in the United States in 2023 are affected by HSV-1 infections.
• In the European Union plus the United Kingdom (EU4 and the UK), the collective number of symptomatic cases of genital herpes stood at approximately 1,204,000 cases in 2023. Among these cases, over 60% were reported in females.
• As per DelveInsight's analysis, around 482,000 cases identified among the total diagnosed genital herpes patients in the seven major markets (7MM) in 2023 are categorized as naïve cases.
• Key Genital Herpes Companies: ModernaTX, Inc., United BioPharma, GlaxoSmithKline, AiCuris, Heidelberg ImmunoTherapeutics, and others
• Key Genital Herpes Therapies: mRNA-1608, UB-621, Non-adjuvanted HSV formulation 1, PRITELIVIR (AIC316), HDIT101, and others
• The Genital Herpes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Genital Herpes pipeline products will significantly revolutionize the Genital Herpes market dynamics.

Genital Herpes Overview
Genital herpes is a sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), primarily HSV-2. It is characterized by painful sores or blisters in the genital or anal area, as well as flu-like symptoms such as fever and swollen lymph nodes. Once infected, the virus remains in the body for life, leading to recurring outbreaks of symptoms.

Get a Free sample for the Genital Herpes Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Herpes Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Genital Herpes Epidemiology Segmentation:
The Genital Herpes market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Genital Herpes
• Prevalent Cases of Genital Herpes by severity
• Gender-specific Prevalence of Genital Herpes
• Diagnosed Cases of Episodic and Chronic Genital Herpes

Download the report to understand which factors are driving Genital Herpes epidemiology trends @ Genital Herpes Epidemiology Forecast
https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Herpes Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Genital Herpes market or expected to get launched during the study period. The analysis covers Genital Herpes market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Genital Herpes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Genital Herpes Therapies and Key Companies
• mRNA-1608: ModernaTX, Inc.
• UB-621: United BioPharma
• Non-adjuvanted HSV formulation 1: GlaxoSmithKline
• PRITELIVIR (AIC316): AiCuris
• HDIT101: Heidelberg ImmunoTherapeutics

Discover more about therapies set to grab major Genital Herpes market share @ Genital Herpes Treatment Landscape
https://www.delveinsight.com/sample-request/genital-herpes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Genital Herpes Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Genital Herpes Companies: ModernaTX, Inc., United BioPharma, GlaxoSmithKline, AiCuris, Heidelberg ImmunoTherapeutics, and others
• Key Genital Herpes Therapies: mRNA-1608, UB-621, Non-adjuvanted HSV formulation 1, PRITELIVIR (AIC316), HDIT101, and others
• Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
• Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Genital Herpes Unmet Needs, KOL's views, Analyst's views, Genital Herpes Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.